212 results about "Pancreas" patented technology

The invention relates to the technical field of medical monitoring, in particular to an intelligent monitoring and health management system for liver, gall and pancreas postoperative drainage fluid, which comprises a data acquisition module for acquiring core specific indexes of liver, gall and pancreas special drainage fluid, visual images of the drainage fluid, dynamic flow and physiological data of a patient; the intelligent analysis module constructs a hepatobiliary pancreatic postoperative exclusive multi-modal model, deeply couples postoperative disease course time sequence characteristics to identify risks at different stages after the operation, and triggers risk assessment when the operation is abnormal; the early warning module is provided with a light, medium and heavy three-level mechanism, and carries out resource adaptation type grading accurate pushing to a responsible physician and a nurse station terminal in combination with a medical care real-time load and a spatial distance. The health management module fuses individual features of the patient and real-time monitoring data, and constructs a personalized rehabilitation scheme in combination with rehabilitation feedback of the patient; and the data synchronization module transmits model update parameters through an encryption channel, and perfects the complete-cycle health archive of the patient. Therefore, the problems that in the prior art, an early warning mechanism is rigid, and data security and full-period management are insufficient are solved.

The present application belongs to the field of aquaculture technology, and mainly relates to a traditional Chinese medicine composition for preventing and treating acute hepatopancreas necrosis disease of prawn, a preparation method and application. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 28-32 parts of Radix Sanguisorbae, 28-32 parts of Radix Scutellariae, 18-22 parts of Phellodendri Cortex and 8-12 parts of Lonicerae Japonicae Flos. The traditional Chinese medicine composition can significantly inhibit the activity of the main pathogen of the disease, i.e. Vibrio parahaemolyticus, improve the immune function and disease resistance of prawn, and further repair the hepatopancreas and intestinal tissues of the diseased prawn, thereby achieving the effect of effectively preventing and treating the acute hepatopancreas necrosis disease of prawn.

To improve allele discrimination, the inventors adapted the system combining Cas13a detection sensitivity with allele-specific PCR amplification to propose CASPER (Cas13a Allele-Specific PCR Enzyme Recognition) as a new versatile, easy-to-implement, and highly sensitive method to detect low-frequency of sequence variant. CASPER enabled specific and sensitive detection of KRASG12D with low DNA input such as DNA extracted from patient's pancreatic ultrasound-guided fine-needle aspiration fluids. CASPER is easy to implement and a versatile reliable method virtually adaptable to any point mutation.

According to an embodiment, disclosed is a system comprising a processor configured to receive an image of a breast of a patient and patient data comprising genetic data; extract features from the image and the patient data, using one or more machine learning models, wherein the features comprise a presence of a calcification and a calcification pattern to generate a breast calcification vector; augment the breast calcification vector with the genetic data; determine, using the machine learning models, a first risk for a breast cancer; a second risk to one or more organs of the patient, wherein the organs comprises one or more of heart, kidney, lungs, pancreas, and brain; predict, a third risk based on one or more of a healing response, a tumor flow and growth, inflammation and degeneration, a disease relapse, an adverse event, and a clinical response; and determine, an overall risk to the patient.

The invention relates to an islet repair ICK mode oral polypeptide optimization system taking VDAC1 as a target based on ESM2 and a genetic algorithm, and the system comprises a mutation module which is used for carrying out mutation and recombination by adopting the genetic algorithm according to original protein sequence data to generate an initial population; the prediction module is used for respectively inputting the protein sequence data of the initial population into a protein dimer dissociation energy prediction model, a protein toxicity prediction model and a protein cell penetrability prediction model to obtain a dissociation energy prediction value delta G, a toxicity probability value T and a cell membrane passing transmission probability Ed; and the optimization module is used for acquiring the optimal individual performance of the highest fitness score to output the Pareto optimal sequence index, and recording the hotspot residue distribution and the site mutation frequency at the same time. On the basis of keeping the biological activity of the original sequence, the key drug properties are improved in a breakthrough manner.

The invention relates to the technical field of medical biology, in particular to a chronic pancreatitis complication risk grading system based on exosome transcriptome data, and aims to solve the problems that existing chronic pancreatitis (CP) typing lacks molecular basis, complication risk prediction is weak and clinical transformation is poor. According to the system, plasma exosomes are extracted and sequenced, a functional characteristic gene set is constructed in combination with pancreas single cell data, CP is divided into three risk increasing subtypes by using a COCA algorithm, and finally 12 core miRNAs are screened to construct a BPNN diagnosis model. The invention proves that the plasma exosome can be used for staging classification of chronic pancreatitis for the first time, miRNA non-invasive accurate layering illness conditions can be detected through qPCR, the risk of fatty diarrhea and 3c type diabetes mellitus can be predicted, and the non-invasiveness, convenience, classification accuracy and result repeatability of the plasma exosome have clinical application and transformation advantages.

Disclosed herein include methods, compositions, and kits suitable for use in cell therapy. In some embodiments, there are provided methods and compositions for differentiating stem cells into pancreatic beta cells capable of producing insulin.

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

Embodiments of the present disclosure relates to uses of ivaltinostat for treating cancers in combination with one or more additional anti-cancer agents, in particular patients with metastatic pancreatic adenocarcinoma.

It is revealed that an organ such as pancreas can be regenerated by utilizing a fact that the deficiency of an organ is complemented by injecting an induced pluripotent stem cell (iPS cell) into a developed blastocyst in a blastocyst complementation method. Thus, the present invention has solved the above-described object. This provides a method for producing a target organ, using an iPS cell, in a living body of a non-human mammal having an abnormality associated with a lack of development of the target organ in a development stage, the target organ produced being derived from a different individual mammal that is an individual different from the non-human mammal.

Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and / or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and / or artificial pancreas (AP) algorithms, for example.

The invention discloses an automatic detection method based on the change rate of the difference between the actual blood glucose values, including: obtaining an actual blood glucose value of the user at the current time; obtaining a historical actual blood glucose value of the user at the previous time, and calculate a difference between the actual blood glucose values at the current time and at the previous time; calculating a change rate of the difference between the actual blood glucose values at the current time; and comparing the change rate of the difference between the actual blood glucose values at the current time with a preset threshold, and determining an event type based on the comparing result. Based on the determined event type, the artificial pancreas can automatically adjust the corresponding infusion strategy to achieve closed-loop control of the artificial pancreas.

The invention relates to a lipid molecule, and a composition and application thereof. The core structure of the lipid-like molecule covers a two-dimensional plane structure and a plurality of three-dimensional structures, and endows the LNP with adjustable membrane tissue characteristics and intracellular transport behaviors, so that a new strategy of adjusting delivery performance from the structural level is realized. In addition, part of the ionizable lipid is introduced into a fluorine substituent group, so that the internal hydrophobic interaction and colloidal stability of the LNP are improved, and the in-vivo delivery persistence is prolonged. The invention also provides a component-simplified LNP delivery system based on programmable regulation and control of ionizable lipid chemical bonds, which is different from the traditional strategy of needing to remove hepatic tropism components (such as cholesterol) or additionally introduce targeted regulation and control lipid (a fifth component) to realize organ targeting. Selective delivery of organs such as liver, spleen, lung, pancreas and the like can be realized under the condition of retaining cholesterol only by changing the type of a chemical bond between an aliphatic chain and a core structure in the ionizable lipid.

The invention provides an application of a carcino-embryonic antigen related cell adhesion molecule 5 (CEACAM5) in treatment of pancreatic cancer. Research finds that a novel stem cell-like cluster cell subtype (hereinafter referred to as' stem cell-like TCs') is found, and the subtype is significantly related to poor prognosis of pancreatic ductal adenocarcinoma patients. Therefore, the invention provides a novel pancreatic ductal adenocarcinoma treatment medicine, namely the carcino-embryonic antigen related cell adhesion molecule 5, which has very positive significance on the treatment of the pancreatic ductal adenocarcinoma.

The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The invention provides a Chinese herbal medicine fermented feed for crayfish and application of the Chinese herbal medicine fermented feed in prevention and control of five-month blast, and belongs to the technical field of aquaculture feeds. A preparation method of the Chinese herbal medicine fermented feed for crayfish comprises the following steps: taking a mixture of artemisia capillaris, potentilla discolor, radix bupleuri, scutellaria baicalensis, golden cypress, astragalus membranaceus, salvia miltiorrhiza, isatis root and liquorice; and inoculating a compound microbial agent consisting of lactobacillus plantarum, bacillus subtilis, bacillus velezensis and saccharomyces cerevisiae for anaerobic fermentation, mixing extract obtained by fermentation with the basal feed, and performing anaerobic fermentation again to obtain the feed. The feed provided by the invention can effectively improve the anti-stress ability and immunity of the crayfish, regulate the hepatopancreas function and remarkably reduce the incidence rate of five-month blast of the crayfish.

The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.

This invention relates to the regulation of pancreatic islet cell differentiation by regulatory factors related to N6-adenosine methylation modification of mRNA. Specifically, it relates to the use of (a) the ALKBH5 gene, or its protein, or its promoter; and / or (b) the YTHDF2 gene, or its protein, or its inhibitor, for the preparation of compositions or formulations for (1) promoting the differentiation of endodermal cells into pancreatic islet precursor cells and / or islet organoids; and / or (2) preventing and / or treating diabetes. The ALKBH5 of this invention regulates the N6-adenosine methylation modification of mRNA by... 6 Modification A controls the in vitro differentiation process of human pancreatic cells. Furthermore, the method of this invention holds promise as an effective method for in vitro culture of pancreatic islet cells, and could subsequently be applied to the treatment of diabetes.

The invention relates to a device for distributing and receiving a population of pancreatic islets heterogeneous in size, the device comprising a matrix having a first face opposite a second face, characterized in that the matrix comprises concentric channels centered on a center O, the channels have an opening for receiving the pancreatic cells, the opening leading out onto the first face, the opening extending over the entire length (L) of the channel, the opening having a width (I) taken along the section Si, the device being configured such that the widths of the opening of two adjacent channels have an equal or increasing value moving away from the center O and such that the widths of the opening of a channel closest to the center O and of a channel furthest from the center O have an increasing value moving away from the center O. The invention relates to the field of implantable devices, in particular artificial pancreas devices.

The invention relates to a method of differentiating pancreatic bi-potent progenitor cells into beta cells comprising cultivating pancreatic endocrine precursor cells in a medium that promotes the cAMP signalling pathway that lies downstream of apical-basal polarity in endocrine precursors, which can be used to increase the differentiation of progenitor cells into beta cells. Furthermore, the present invention relates to a method of enriching and / or isolating one or more cells expressing a marker of apical-basal polarity, thereby isolating beta cells, and to a method of producing a population of beta cells from a population of human embryonic stem cells. Furthermore, the present invention relates to a population of beta cells obtainable by the method, a pharmaceutical composition comprising the beta cells, a cell culture of progenitor cells in a medium comprising a cAMP agonist, a complex comprising a beta cell bound by the binding agents specific for CD133 and CD49a, and a use of specific binding partners for isolating beta cells.

The present application belongs to the field of biotechnology, and particularly relates to a carboxypeptidase B (CPB) precursor gene sequence, a recombinant carboxypeptidase B precursor and a preparation method of carboxypeptidase B. The carboxypeptidase B precursor gene sequence is shown in SEQ ID No. 6, the amino acid sequence is shown in SEQ ID No. 5, the gene sequence of the CPB enzyme is shown in SEQ ID No. 2, and the amino acid sequence is shown in SEQ ID No. 4. The preparation method of CPB comprises the following steps: (1) cloning and construction of a CPB enzyme expression vector; (2) expression of CPB precursor protein by using an engineering bacterium to form an inclusion body; (3) washing, crushing and centrifugation of the bacterium, collection of the inclusion body, denaturation and dissolution; (4) renaturation of the inclusion body; and (5) CPB activation and purification. The process steps of the present application are simple, animal pancreas is not used, and the possibility of infection is reduced; the specific activity of the obtained CPB enzyme is high, the yield per liter of fermentation liquid is high, and the present application is suitable for large-scale production and application.

The invention relates to the technical field of food processing, in particular to a method for enhancing the bean flavor of soybean milk and reducing the beany flavor through composite enzymolysis and bacterium fermentation. According to the method for enhancing the bean flavor of the soybean milk and reducing the beany flavor through the combination of the composite enzymolysis and the bacterium fermentation, the soybeans are firstly soaked, then the soaked soybeans are mixed with water, and the mixture is ground and cooked to obtain original soybean milk; adding porcine pancreas lipase into the original soybean milk to carry out enzymolysis, then adding alkaline protease to carry out enzymolysis, and then carrying out enzyme deactivation to obtain enzymolysis soybean milk; and performing sterilization treatment on the enzymolysis soybean milk, and then inoculating lactobacillus gasseri for fermentation treatment to obtain a fermented soybean milk finished product. According to the method disclosed by the invention, the beany flavor and the bean flavor of the soybean milk are taken as a comprehensive target, and the bean flavor can be effectively improved on the basis of removing the beany flavor through organic combination of enzyme treatment and microbial fermentation, so that a theoretical basis can be provided for accurate regulation and control of the flavor of the soybean milk, and a technical support can be provided for processing and production of high-quality soybean milk.

This invention discloses a method for detecting mitochondrial membrane potential in the gills or hepatopancreas of crustaceans, belonging to the field of mitochondrial membrane potential detection technology. This invention, by addressing the structural and physiological differences between gill and hepatopancreas tissues in crustaceans, formulates differentiated incubation strategies: for gill tissue, a "live pre-equilibration-short-time staining-rapid slide preparation" method is used, strictly controlling the JC-1 incubation time to within 10 minutes to effectively avoid probe toxicity damage to mitochondria; for hepatopancreas tissue, in vivo incubation is extended to 1 hour to ensure sufficient dye penetration. Under the condition of uniformly using 2 μM JC-1 and 20 μmol / L CCCP as positive controls, this method significantly improves the tissue penetration and signal uniformity of the dye, solving problems such as uneven staining and weak signal caused by exoskeleton barriers and high lipid content, providing reliable technical support for aquatic health assessment and toxicology research.

The invention discloses a pancreas image enhancement and big language model image classification method based on a deep learning network, and the system converts low-illumination abdomen image data into a high-illumination easy-to-observe image based on a deep learning algorithm, and achieves the classification of the abdomen image data through combining with a big language model. Specifically, the method comprises the following steps: 1) constructing a self-supervised zero sample denoising module; (2) an image enhancement module based on Transform is constructed; and 3) developing an image classification module based on a large language model. According to the method, image enhancement, recognition and classification are carried out on the abdominal plain film image features, the difficulties that feature quantification is difficult due to the fact that the pancreas boundary of a traditional iconography image is fuzzy, deviation is prone to occurring due to manual subjective judgment and the like are overcome, and the accuracy and efficiency of image feature processing are remarkably improved. And meanwhile, pancreas related image feature classification is performed on the image data by using a large language model, so that differentiated identification and annotation of the pancreas images are realized.

Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.

The disclosure relates to targeted Chromatin Accessibility and Mutation Sequencing (tCAM-seq) for parallel analysis of genetic and epigenetic analysis of patients with pancreatic adenocarcinoma (PDAC) to 1) determine responsiveness to standard of care chemotherapy, and 2) identify actionable allelic variant mutations that can be used to guide treatment decisions. Prognostic methods and treatment strategies are also provided.

This provides an unlimited supply method for human β-cells from stem cells. [Solution] Compositions and methods for promoting the differentiation of stem cells into beta cells using one or more epigenetically modified compounds are disclosed herein. The disclosure also relates to compositions and methods for selecting and enriching differentiated beta cells. The disclosure also relates to compositions and methods for irradiating a cell population to reduce proliferation. In some embodiments, methods are provided herein, comprising the step of contacting a population of pancreatic progenitor cells or their precursors with an epigenetically modified compound, wherein the contact step results in a population of endocrine cells in which the proportion of chromogranin A-positive (CHGA+) cells or C-peptide-positive and NKX6.1-positive (C-PEP+, NKX6.1+) cells is increased compared to a corresponding population of endocrine cells that have not been contacted with the epigenetically modified compound.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.